SYK250117P250000
- 0.06
- 0.000.00%
Stryker Corp Newsroom
Express News | CITIC SEC: The year of mass production for Optimus is expected to inject strong confidence into the humanoid robot Sector.
Unpleasant Surprises Could Be In Store For Stryker Corporation's (NYSE:SYK) Shares
Bernstein Adjusts Price Target on Stryker to $425 From $410, Keeps Outperform Rating
Musk: The goal this year is to produce thousands of Siasun Robot&Automation humanoid robots, with production increasing tenfold each year over the next two years.
Musk stated that if everything goes smoothly, the production of humanoid robots will increase tenfold by 2026, with the goal of producing between 0.05 million to 0.1 million humanoid robots next year, and then increasing it tenfold again the following year.
Bernstein Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $425
Bernstein Maintains Stryker Corp(SYK.US) With Buy Rating, Raises Target Price to $410
A Quick Look at Today's Ratings for Stryker Corp(SYK.US), With a Forecast Between $394 to $450
NVIDIA open-sources the world's foundational models, humanoid robots accelerate towards the 'ChatGPT moment'.
① Recently, NVIDIA launched the physical AI model Cosmos, which is capable of predicting environments such as warehouses and road conditions to train Siasun Robot&Automation; ② According to NVIDIA's disclosed list, the first batch of users for Cosmos includes manufacturers such as 1X, Agility, Figure AI, and Xiaopeng Autos; ③ Brokerages believe that in the collection methods of training data for humanoid robots, synthetic data will greatly promote the development of robots.
BTIG Sticks to Their Buy Rating for Stryker (SYK)
The medical device company Stryker plans to acquire Inari for 4.9 billion US dollars.
On January 8, Glonghui reported that the medical device manufacturer Stryker announced it would acquire Inari Medical at a price of $80 per share, with a total transaction amount of approximately $4.9 billion. Stryker produces a variety of medical products, from hospital beds and other furniture to cleaning products, as well as orthopedic and neuro-surgical tools. Inari focuses on diseases such as venous thromboembolism or patients' venous thrombus, providing surgical products.
Penumbra Spikes After Stryker- Inari Deal
JMP Securities Reiterates Market Perform on Strykerto Market Perform
RBC Capital Reiterates Outperform on Stryker, Maintains $425 Price Target
Express News | Inari Medical surged over 20% after Stryker Corp announced it would acquire the company.
Sector Update: Health Care Stocks Mixed Premarket Tuesday
Sector Update: Health Care
U.S. stocks preview | "CES Technology Spring Festival" is buzzing! NVIDIA reached a historic high in pre-market trading; the "golden touch magic" is back, with NVIDIA concept stock Aurora soaring nearly 40%.
The investment director at Morgan Stanley states that US stocks may face severe challenges in the next six months due to rising bond yields and the strengthening dollar raising concerns about inflation; a Wall Street bond short seller predicts that the yield on ten-year USA Bonds will rise to 5.5% by the end of the year; under the impact of high interest rates, the bankruptcy rate of American companies has reached its highest level since the financial crisis.
A Quick Look at Today's Ratings for Stryker Corp(SYK.US), With a Forecast Between $400 to $445
Stryker Analyst Ratings
Stocks Mostly Rise Pre-Bell Ahead of Key Jobs Data; Asia, Europe Strong